DRTS Stock Analysis: Buy, Sell, or Hold?
DRTS - Alpha Tau Medical Ltd. Ordinary Shares
$7.32
0.02 (0.27%)
▲
5d:
-9.41%
30d:
+11.75%
90d:
-3.69%
HOLD
LOW Confidence
Analysis Updated: Apr 28, 2026 12:00 AM ET
Earnings: May 18, 2026
18d
Smart Money Accumulation
DRTS is down 9.4% this week, but smart money is accumulating calls. Top strike: $10 2026-06-18 with 221 OI. Call ratio: 100% View Scanner →
Strength: 9.7/10
Get Alerted When DRTS Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 HOLD: DRTS shows balanced signals. Fine to hold or accumulate slowly. Monitor for clearer direction.
📊 HOLD: DRTS shows balanced signals. Fine to hold or accumulate slowly. Monitor for clearer direction.
In-depth Analysis How we analyze
Valuation Analysis: DRTS is currently trading at $7.32, which is considered fair relative to its 30-day fair value range of $6.95 to $7.89.
Technical Outlook: Technically, DRTS is in a strong uptrend. The price is currently testing key support at $7.15. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: The stock shows a mixed technical setup (40/100), with neutral trendline and momentum signals. In the options market, Implied Volatility is low (11th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. Wall Street analysts see significant upside, with an average price target of $9.50 (+30.1%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Technical Outlook: Technically, DRTS is in a strong uptrend. The price is currently testing key support at $7.15. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: The stock shows a mixed technical setup (40/100), with neutral trendline and momentum signals. In the options market, Implied Volatility is low (11th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. Wall Street analysts see significant upside, with an average price target of $9.50 (+30.1%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Quick Decision Summary
Current Position
FAIR
Historical Trading Range
$6.95 -
$7.89
Company Quality Score
54/100
(HOLD)
Options IV Signal
11th percentile
(LOW)
Volume Confirmation
HIGH
Confidence Score
80.0%
All Signals
- NEUTRAL: Price in fair range
- BULLISH: Options cheap (IV 11th percentile)
- NEUTRAL: Mixed technical signals (40/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 30.1% below Wall St target ($9.50)
- CAUTION: Recommendation downgraded due to -9.4% 5-day decline
Trading Range Analysis
30-Day Trading Range
$6.95 -
$7.89
Current vs Trading Range
FAIR
Expected Move (7 Days)
±$0.93
(12.6%)
Support & Resistance Levels
Support Level
$7.15
Resistance Level
$8.44
Current Trend
Strong Uptrend
Technical data as of
Apr 29, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-17.14
Wall Street Target
$9.50
(+30.1%)
Share & Embed Analysis
Last updated: April 29, 2026 12:40 PM ET
Data refreshes hourly during market hours. Next update: 1:40 PM
Data refreshes hourly during market hours. Next update: 1:40 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is DRTS showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
ACLX
Arcellx Inc |
STRONG BUY
18 analysts |
$113 | 57 HOLD |
|
MLTX
MoonLake Immunotherapeut… |
STRONG BUY
16 analysts |
$27 | 57 HOLD |
|
BNTX
BioNTech SE |
STRONG BUY
21 analysts |
$131 | 55 HOLD |
|
BBIO
BridgeBio Pharma Inc |
STRONG BUY
19 analysts |
$101 | 53 HOLD |
|
GPCR
Structure Therapeutics I… |
STRONG BUY
14 analysts |
$109 | 53 HOLD |
